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Abstract: Five new nardosinane-type sesquiterpenoids, paralemnolins Q–U (1–5), along 
with three known compounds (6–8), were isolated from the Formosan soft coral 
Paralemnalia thyrsoides. The structures of new metabolites were elucidated on the basis of 
extensive spectroscopic methods, and the absolute configuration of 1 was determined by 
the application of Mosher’s method on 1. Among these metabolites, 1 and 3 are rarely 
found nardosinane-type sesquiterpenoids, possessing novel polycyclic structures. 
Compounds 1, 3, 6 and 7 were found to possess neuroprotective activity. 
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1. Introduction 
Soft corals of the genus Paralemnalia [1−7] and Lemnalia [8−12] have been found to be rich sources 
of sesquiterpenoids of nardosinane [1−3,9,12,13], neolemnane [3,4,10,11] and africanane-type [3,8] 
compounds and  norsesquiterpenoids of nornardosinane-type [3,5,6,9,10] compounds. Our previous 
study on the secondary metabolites of a Taiwanese soft coral Paralemnalia thyrsoides, collected from 
the coast of Green Island, has resulted in the isolation of two norsesquiterpenoids [6],   
ten sesquiterpenoids [4,6,7] and three novel sesquiterpenoids
 derived from a nardosinane precursor [7]. 
In our continuing search for new and bioactive metabolites from Formosan soft corals,   
Paralemnalia thyrsoides collected from Orchid Island were chemically investigated for the first time, 
and the investigation has resulted in the isolation of five new nardosinane-type sesquiterpeneoids, 
paralemnolins Q–U (1–5), along with three known compounds 2-deoxylemnacarnol (6) [2],   
2-deoxy-7-O-methyllemnacarnol (7) [14] and 2-oxolemnacarnol (8) [15] (Chart 1). The structures of 
sesquiterpenoids 1–5 were elucidated by spectroscopic analysis and the absolute configurations were 
established by application of modified Mosher’s method on 1 [16]. The inhibitory activity of 
compounds  1–8 against three human cancer cell lines was investigated, however, none of these 
metabolites was found to possess useful cytotoxicity. Furthermore, a study of the neuroprotective 
effect of these metabolites revealed that 1,  3,  6 and 7, in particular 6, could reduce 6-OHDA   
(6-hydroxydopamine)-induced neurotoxicity in neuroblastoma SH-SY5Y cells. 
Chart 1. Structures of metabolites 1–8. 
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2. Results and Discussion 
Paralemnolin Q (1) was obtained as a white powder. The HRESIMS (m/z 273.1468 [M + Na]
+) of 1 
established the molecular formula C15H22O3, appropriate for five degrees of unsaturation, and its IR 
spectrum revealed the presence of carbonyl (1735 cm
−1) and hydroxy (3429 cm
−1) groups. The 
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and DEPT (Table 1) spectroscopic data showed signals of three methyls, three sp
3 methylenes 
(including one oxymethylene appearing at δC 69.5), five sp
3 methines, one sp
2 methine, one sp
3 and 
two sp
2 quaternary carbons (including one carbonyl carbon appearing at δC 211.6). The above data 
accounted for two of the five degrees of unsaturation, indicating a tricyclic structure for 1. From the 
COSY spectrum measured in CDCl3, it was possible to establish four proton sequences from H-1 to 
H2-3, H-4 to H3-14, H-8 to H-9 and H-11 to H3-13 (Figure 1). Key HMBC correlations of H-6 to C-7; 
H-8 to C-7 and C-10; H-9 to C-1; H3-13 to C-6, C-11 and C-12; H3-14 to C-3, C-4 and C-5; and H3-15 
to C-4, C-5, C-6 and C-10, permitted the connection of the carbon skeleton. Furthermore, the HMBC 
cross-peak from H-8 to C-12 suggested that C-8 and C-12 were linked through an oxygen to form a 
tetrahydropyran ring. On the basis of the above analysis, the gross planar structure of 1 was established. 
Table 1. 
13C NMR data for compounds 1–5. 
Position 1, 
a δC, mult. 2 , 
b δC, mult. 3 , 
a δC, mult. 4 , 
a δC, mult. 5 , 
a δC, mult. 
1 69.5,  CH 
c  73.1, CH  59.0, CH  118.5, CH  121.7, CH 
2 36.4,  CH2 29.4,  CH2 25.5,  CH2  77.8, CH  80.8, CH 
3 28.8,  CH2 24.1,  CH2 23.3,  CH2 30.5,  CH2 31.1,  CH2 
4  36.3, CH  30.0, CH  32.5, CH  29.2, CH  33.7, CH 
5  48.7, C  41.0, C  37.6, C  41.0, C  40.9, C 
6  60.6, CH  56.9, CH  61.6, CH  58.9, CH  59.1, CH 
7  211.6, C  201.8, C  210.6, C  107.3, C  107.5, C 
8  73.7, CH  133.9, CH  40.3, CH2 33.2,  CH2 33.4,  CH2 
9  111.3, CH  143.6, CH  78.2, CH  27.6, CH2 27.4,  CH2 
10  156.6, C  74.9, C  62.8, C  149.7, C  145.2, C 
11  35.3, CH  26.4, CH  32.0, CH  37.1, CH  37.2, CH 
12 61.9,  CH2 64.6,  CH2 67.6,  CH2 72.2,  CH2 72.2,  CH2 
13 18.8,  CH3 14.9,  CH3 17.2,  CH3 18.7,  CH3 18.6,  CH3 
14 14.2,  CH3 13.8,  CH3 14.5,  CH3 15.9,  CH3 16.3,  CH3 
15 19.5,  CH3 17.6,  CH3 17.7,  CH3 19.7,  CH3 21.1,  CH3 
a Spectrum recorded at 100 MHz in CDCl3; 
b 125 MHz in CDCl3; 
c Attached protons deduced by   
DEPT experiment. 
Figure 1. Selected 
1H−
1H COSY (▬) and HMBC (→) correlations of 1–3. 
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The relative configuration of 1 was elucidated by the analysis of NOE correlations, as shown in 
Figure 2. It was found that H3-15 (δH 0.98, s) showed NOE interactions with H-1 (δH 4.22, dd, J = 12.0, 
4.8 Hz), H-6 (δH 2.10, brs), and H3-14 (δH 0.79, d, J = 6.4 Hz); therefore, assuming the β-orientation of 
H3-15, all of H-1, H-6, and H3-14 should also be positioned on the β face. Furthermore, H-4 (δH 2.02, 
ddq, J = 12.0, 4.0, 6.4 Hz) exhibited NOE correlations with H-11 (δH 2.39, ddq, J =3.6, 3.2, 7.2 Hz) 
and one proton of H2-12 (δH 4.18, dd, J = 12.0, 3.2 Hz), revealing the α-orientation of H-11, and the  
β-orientations of H-8 and H3-13. On the basis of the above findings and other detailed NOE 
correlations (Figure 2), the relative structure of 1 was determined. In order to resolve the absolute 
structure of 1, we determined the absolute configuration at C-1 using a modified Mosher’s   
method [15]. The (S)- and (R)-MTPA esters of 1 (1a and 1b, respectively) were prepared using the 
corresponding  R-(−)- and S-(+)-α-methoxy-α-(trifluoromethyl)phenylacetyl chlorides, respectively. 
The determination of the chemical shift differences (δS − δR) for the protons neighboring C-1 led to the 
assignment of the S configuration at C-1 of 1 (Figure 3). Thus, the absolute configuration of 1 has  
been determined. 
Figure 2. Key NOESY correlations for 1–3. 
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Figure 3. 
1H NMR chemical shift differences of MTPA esters of 1. 
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The HRESIMS spectrum of paralemnolin R (2) showed a molecular formula of C15H22O3, the same 
as that of 1. The NMR data revealed the presence of an α,β-unsaturated ketone (δC 201.8 C), and one 
trisubstituted double bond (δC 143.6 CH, 133.9 CH). The above functionalities account for two of the 
five degrees of unsaturation, suggesting a tricyclic structure in 2. 
1H–
1H COSY and HMBC spectra 
(Figure 1) further revealed that 2 possesses an α,β-unsaturated ketone at C-7(C=O), C-8 and C-9. 
Furthermore, the HMBC cross-peak from H-12 to C-10 suggested that C-10 and C-12 are linked 
through an oxygen. On the basis of the above observations, and by the assistance of additional 2D 
NMR (
1H–
1H COSY and HMBC) correlations, it was possible to establish the planar structure of 2 as 
illustrated in Figure 1. The relative configurations of the six chiral centers at C-1, C-4, C-5, C-6, C-10 
and C-11 in 2 were further determined on the basis of NOE correlations (Figure 2). It was found that 
H3-15 showed NOE interactions with both H3-14 and H-6, while H-4 was NOE correlated with H-11. 
Therefore, H-6, H3-14 and H3-15 were positioned on the same β-face, and in contrast, H-4 and H-11 
should be placed on the α-face. Moreover, one of the methylene protons at C-2 (δH 2.18, dddd,   
J = 15.0, 15.0, 5.0, 3.5 Hz) exhibited NOE correlations with H-4 and was assigned as H-2α. The NOE 
correlation observed between H-2α and H-1 reflected the β-orientation of hydroxy group. Further NOE 
analysis revealed that 2 possesses the same configurations at C-4, C-5, C-10, and C-11, as in known 
compounds flavalins B-D [12]. Thus, the structure of 2 was fully established. 
The HRESIMS of paralemnolin S (3) showed that it possesses the molecular formula C15H22O3  
(m/z 251.1634 [M + H]
+). The IR spectrum of 3 showed the absorption of a carbonyl group (1719 cm
−1). 
The NMR data showed the presence of one trisubstituted epoxide (δH 3.31, 1H, brs; δC 62.8, C and 
59.0, CH), and one ketone (δC 210.6, C). The above functionalities and 
1H and 
13C NMR spectroscopic 
data (Tables 1 and 2) showed a polycyclic structure in 3. On the basis of the above results and by the 
assistance of 
1H–
1H COSY and HMBC spectroscopic analyses (Figure 1), the molecular framework  
of  3  could be established. This metabolite was found to be a rare nardosinane containing an 
oxacycloheptane. The 4S*, 5S*, 11R* configurations of 3 were revealed from the similar NOE 
interactions (Figure 2) as in 1 and 2. Moreover, by NOESY spectrum (Figure 2), it was found that the 
α-oriented H-1 showed NOE interactions with H2-2, but not with H3-15, indicating the α-orientation of 
H-1. Furthermore, the NOE correlation observed between one proton (δH 2.80, dd, J =19.2, 2.8 Hz) of 
H2-8 with H3-15 and H-9 reflected the β-orientation of H-9. From the above evidences and the other 
NOE correlations (Figure 3), the structure of 3 was determined. 
The HRESIMS of paralemnolin T (4) showed that it possesses the molecular formula C15H24O4  
(m/z 269.1742 [M + H]
+). The IR spectrum of 4 showed the absorption of a hydroxy group (3361 cm
−1). 
Comparison of the 
1H and 
13C NMR spectroscopic data (Tables 1 and 2) of compounds 4 and 8 [15] 
suggested that the structure of 4 should be very similar to that of 8, with the exception of signals 
assigned to C-2, where a ketone (δC 198.0, C) in 8 was replaced by one hydroperoxy-bearing methine 
(δH 4.37, 1H, t, J = 4.0 Hz, δC 77.8, CH) in 4. Furthermore, H3-15 was found to show NOE correlations 
with H-6, H3-14 which further correlates with H3-13, and one proton of H2-3 (δH 1.57, m), and the 
other proton of H2-3 (δH 1.93, m) showed an NOE correlation with hydroperoxy proton (δH 7.83, brs), 
suggesting that H-2, H-6, H3-13, H3-14 and H3-15 should be placed on the same β-face and in contrast, 
hydroperoxy group should be positioned on the α-face. Further analysis of other NOE correlations 
revealed that 4 possesses the same relative configurations at C-4, C-5, C-6, C-7 and C-11 as those of 8 
(Figure 4). Based on the above results, the structure of 4 was established. Mar. Drugs 2011, 9  
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Table 2. 
1H-NMR spectral data for compounds 1–5. 
Position  1, 
a δH (J in Hz) 
c  2, 
b δH (J in Hz)  3, 
a δH (J in Hz)  4, 
a δH (J in Hz)  5, 
a δH (J in Hz)
1  4.22, dd (12.0, 4.8) 
c  3.81, brs  3.31, brs  5.57, dd (4.0, 1.6)  5.60, brs 
2  2.19, dddd 
(14.0, 4.8, 2.4, 2.4)
2.18, dddd 
(15.0, 15.0, 5.0, 3.5)
2.19, dddd 
(15.6, 4.8, 2.4, 2.4) 
4.37, t (4.0)  4.59, t (7.2) 
  1.48, m  1.65, m  1.92, dddd 
(15.6, 12.0, 6.0, 1.6)
  
3  1.74, ddd 
(14.0, 4.0, 4.0, 4.0)
1.70, m  1.37, m  1.93, m  1.84, m 
  1.57, m  1.37, m  1.24, m  1.57, m  1.56, m 
4  2.02, ddq 
(12.0, 4.0, 6.4) 
2.55, ddq 
(15.5, 3.5, 7.0) 
1.73, ddq 
(12.4, 2.8, 6.8) 
2.02, ddq 
(12.8, 3.2, 6.8) 
1.95, m 
6  2.10, brs  2.25, d (5.0)  2.40, m  1.82, m  1.80, m 
8  4.10, d (6.4)  6.39, s  2.80, dd (19.2, 2.8)  1.94, m  1.95, m 
     2.64, dd (19.2, 2.8)  1.82, m  1.79, m 
9  5.77, dd (6.4, 2.4)  6.39, s  3.53, t (2.8)  2.44, m; 2.30, m  2.46, m; 2.26, m
11  2.39, ddq 
(3.6, 3.2, 7.2) 
2.36, m  2.38, m  1.92, m  1.91, m 
12  4.18, dd (12.0, 3.2) 3.75, dd (12.5, 6.5)  3.81, dd (13.2, 4.8)  3.87, t (8.8)  3.88, t (8.8) 
  3.38, dd (12.0, 1.2) 3.19, dd (12.5, 12.5) 3.31, dd (13.2, 9.6)  3.48, t (8.8)  3.49, t (8.8) 
13  1.10, d (7.2)  0.70, d (7.0)  0.93, d (7.2)  1.10, d (5.2)  1.09, d (6.0) 
14  0.79, d (6.4)  0.75, d (7.0)  0.76, d (6.8)  0.90, d (6.8)  0.92, d (6.8) 
15  0.98, s  1.06, s  0.87, s  1.11, s  1.18, s 
a Spectrum recorded at 400 MHz in CDCl3; 
b 500 MHz in CDCl3; 
c J values in Hz in parentheses. 
Figure 4. Key NOE correlations of 4 and 5. 
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Paralemnolin U (5) was isolated as a white solid. Its HRESIMS exhibited a [M + H]
+ ion peak at 
269.1746  m/z,  establishing a molecular formula of C15H24O4. By 2D NMR spectroscope data, 
including COSY, HMQC, and HMBC, compound 5 was shown to possess the same molecular 
framework as that of 4. Furthermore, the NMR data of 5 were very similar to those of 4, suggesting 
that 5 is an isomer of 4. By NOESY spectrum (Figure 2), it was found that the β-oriented H3-15 Mar. Drugs 2011, 9  
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showed NOE correlations with one proton of H2-3 (δH 1.56, m) and the other proton of H2-3 (δH 1.84, m) 
showed NOE correlation with H-2, indicating the β-orientation of the hydroperoxy group. On the basis 
of the above findings and other NOE correlations (Figure 4), 5 was revealed to be the C-2   
epimer of 4. 
In order to explore the biological activities of the isolated compounds, cytotoxicity of these 
compounds against the proliferation of a limited panel of cancer cell lines, including mouse melanoma 
(B16), human epithelial carcinoma (HeLa), human hepatoma carcinoma (HepG2) cell lines, was 
evaluated. The results showed that all of the compounds were not cytotoxic toward the above cancer 
cells (IC50’s > 20 µg/mL). Furthermore, the neuroprotective assay of 1–8 using 6-OHDA-induced 
neurotoxicity in neuroblastoma SHSY5Y, a human dopaminergic neuron often used for study of 
Parkinson’s disease [17], was performed by a method reported previously [18]. It was observed that 
the cytotoxicity of 6-OHDA on SH-SY5Y cells could be reduced by pretreatment with 1, 3, 6 and 7 at 
various concentrations. The relative neuroprotective activities of 1 at 10
−2, 10
−1, 1 and 10 µM were  
8.7 ± 2.5, 20.2 ± 14.0, 16.2 ± 3.5 and 11.2 ± 1.3%, 3 at 10
−4, 10
−3, 10
−2 and 10
−1 µM were 6.1 ± 2.6, 
16.2 ± 5.1, 25.2 ± 3.4 and 10.2 ± 5.3%, 6 at 10
−2, 10
−1, 1 and 10 µM were 10.1 ± 1.9, 44.8 ± 4.5,  
30.2 ± 1.2 and 38.9 ± 2.7%, and 7 at 10
−4, 10
−3 and 10
−2 µM were 13.5 ± 3.5, 24.5 ± 7.9 and   
16.7 ± 2.2%, respectively (Figure 5). From the neurological activity results, we suggest that further 
investigation of 1,  3,  6 and 7 for their therapeutic potential against neurodegenerative diseases   
is worthwhile.  
Figure 5. The neuroprotective effects of 1, 3, 6 and 7 on 6-OHDA-induced neurotoxicity 
in human neuroblastoma SH-SY5Y cells. SH-SY5Y cells were pre-incubated for 1 h with 
the indicated concentration of test compound and then stimulated with 6-OHDA (20 µM) 
or vehicle. Relative neuroprotection of control (without the treatment of 6-OHDA and 
compound) and 6-OHDA-treated alone group were taken to be 100% and 0%, respectively. 
The experiment was repeated three times. * Significantly different from the 6-OHDA-treated 
alone group (P < 0.05). 
 Mar. Drugs 2011, 9  
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3. Experimental Section 
3.1. General Experimental Procedures 
Melting points were determined using a Fisher-Johns melting point apparatus. Optical rotations 
were measured on a JASCO P-1020 polarimeter. Ultraviolet spectrum was recorded on a JASCO  
V-650 spectrophotometer. IR spectra were recorded on a JASCO FT/IR-4100 infrared 
spectrophotometer. The NMR spectra were recorded on a Varian 400MR FT-NMR (or Varian Unity 
INOVA500 FT-NMR) instrument at 400 MHz (or 500 MHz) for 
1H and 100 MHz (or 125 MHz) for 
13C in CDCl3. ESIMS data were obtained with a Finnigan LCQ ion-trap mass spectrometer. HRESIMS 
data were recorded on a LTQ Orbitrap XL mass spectrometer. Silica gel (Merck, 230–400 mesh) was 
used for column chromatography. Precoated silica gel plates (Merck, Kieselgel 60 F-254, 0.2 mm) 
were used for analytical TLC. High-performance liquid chromatography was performed on a Hitachi 
L-2455 HPLC apparatus with a Supelco C18 column (250 × 21.2 mm, 5 µm). 
3.2. Animal Material 
Soft coral P. thyrsoide was collected by hand using SCUBA off the coast of Orchid Island, located 
off Taiwan’s southeastern coast, in August 2008, at a depth of 10–15 m, and stored in a freezer until 
extraction. A voucher sample was deposited at the Department of Marine Biotechnology and 
Resources, National Sun Yat-sen University. 
3.3. Extraction and Separation 
The frozen bodies of P. thyrsoide (3.1 kg, wet wt) were sliced and exhaustively extracted with 
dichloromethane (1 × 10 L). The EtOAc extract (30.4 g) was chromatographed over silica gel by 
column chromatography and eluting with EtOAc in n-hexane (0–100%, stepwise) then with acetone in 
EtOAc (50–100%, stepwise) to yield 30 fractions. Fraction 21, eluting with n-hexane–EtOAc (2:1), 
was further purified over silica gel using n-hexane–acetone (7:1) to afford six subfractions (A1–A6). 
Subfraction A2 was separated by reversed-phase HPLC using MeOH–H2O (4:1) to afford 4 (1.8 mg), 
5 (0.6 mg), 6 (18.3 mg) and 7 (8.8 mg), and subfraction A4 was separated by reversed-phase HPLC 
using MeOH–H2O (2:1) to afford 1 (10.2 mg), 2 (14.6 mg), 3 (0.8 mg) and 8 (5.1 mg). 
Paralemnolin Q (1): white solid; mp 118 °C; [α]
26
D +26 (c 0.24, CHCl3); IR (neat) νmax 3429, 
2963, 2931, 2877 and 1735 cm
−1; 
13C and
 1H NMR data, see Tables 1 and 2; ESIMS m/z 273  
[M + Na]
+; HRESIMS m/z 273.1468 [M + Na]
+ (calcd for C15H22O3Na, 273.1467). 
Paralemnolin R (2): white solid; mp 120 °C; [α]
26
D −42 (c 1.46, CHCl3); UV (MeOH) λmax 211  
(log ε = 3.5); IR (neat) νmax 3401, 2960, 2937 and 1654 cm
−1; 
13C and 
1H NMR data, see Tables 1 and 2; 
ESIMS m/z 273 [M + Na]
+; HRESIMS m/z 273.1465 [M + Na]
+ (calcd for C15H22O3Na, 273.1467). 
Paralemnolin S (3): colorless oil; [α]
24
D +83 (c 0.08, CHCl3); IR (neat) νmax 2958, 2933, 2881, 1719 
and 1676 cm
−1; 
13C and 
1H NMR data, see Table 1; ESIMS m/z 251 [M + H]
+; HRESIMS   
m/z 251.1634 [M + H]
+ (calcd for C15H23O3, 251.1642). Mar. Drugs 2011, 9  
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Paralemnolin T (4): colorless oil; [α]
24
D −28 (c 0.18, CHCl3); IR (neat) νmax 3361, 2933, 2881 and 
1652 cm
−1; 
13C and 
1H NMR data, see Table 1; ESIMS m/z 269 [M + H]
+; HRESIMS m/z 269.1742  
[M + H]
+ (calcd for C15H25O4, 269.1747). 
Paralemnolin U (5): colorless oil; [α]
24
D −140 (c 0.06, CHCl3); IR (neat) νmax 3365, 2937, 2877 and 
1652 cm
−1; 
13C and 
1H NMR data, see Table 1; ESIMS m/z 269 [M + H]
+; HRESIMS m/z 269.1746  
[M + H]
+ (calcd for C15H25O4, 269.1747). 
Preparation of (S)- and (R)-MTPA esters of 1. To a solution of 1 (1.0 mg) in pyridine (0.1 mL) was 
added (R)-MTPA chloride (10 µL), and the mixture was allowed to stand for 12 h at room temperature. 
After the evaporation of the solvent, the residue was subjected to short silica gel column 
chromatography using n-hexane−acetone (6:1) to yield the (S)-MTPA ester, 1a (0.4 mg). The   
same procedure was applied to obtain the (R)-MTPA ester 1b (0.9 mg) from the reaction of   
(S)-(+)-α-methoxy-α-(trifluoromethyl)phenylacetyl chloride with 1. Selective 
1H-NMR (CDCl3, 
400 MHz) data of 1a: δ 2.237 (1H, m, H-2a), 1.513 (1H, m, H-2b), 1.757 (1H, m, H-3a), 1.641 (1H, m, 
H-3b), 2.123 (1H, brs, H-6), 3.992 (1H, d, J = 6.4 Hz, H-8), 5.488 (1H, dd, J = 6.4, 2.0 Hz, H-9),  
1.091 (3H, d, J = 6.8 Hz, H-13), 0.801 (3H, d, J = 6.8 Hz, H-14), 1.046 (3H, s, H-15); selective  
1H NMR (CDCl3, 400 MHz) data of 1b: δ 2.256 (1H, m, H-2a), 1.656 (1H, m, H-2b), 1.788 (1H, m,  
H-3a), 1.656 (1H, m, H-3b), 2.106 (1H, brs, H-6), 3.863 (1H, d, J = 6.8 Hz, H-8), 5.152 (1H, dd,  
J = 6.4, 2.0 Hz, H-9), 1.078 (3H, d, J = 6.8 Hz, H-13), 0.804 (3H, d, J = 6.8 Hz, H-14), 1.038 (3H,  
s, H-15). 
3.4. Cytotoxicity Testing  
Cell lines were purchased from the American Type Culture Collection (ATCC). Cytotoxicity assays 
of compounds 1–8 were performed using the Alamar Blue assay [19,20]. 
3.5. Neuroprotective Activity Assay 
The method for neuroprotective assay was modified from previous study [18]. The human 
neuroblastoma SH-SY5Y cell line was cultured on 96-well plates. Compounds 1–8 were added to the 
cells 1 h before 20 µM 6-hydroxydopamine (6-OHDA) challenge. After 15 h incubation, 10 µL of 
Alamar Blue (Biosource, CA, USA) was aseptically added. The percentages of neuroprotection in  
6-OHDA alone and control (without 6-OHDA and test compounds) groups were defined as 0% and 
100%, respectively. 
4. Conclusions  
Our present investigation demonstrated that the Formosan soft coral Paralemnalia thyrsoides is a 
good source of bioactive substances. In our investigation of new and bioactive metabolites from the 
Formosan soft corals, this is the first study of P. thyrsoides collected from Orchid Island. From the 
neurological activity results, compounds 1,  3,  6 and 7, in particular 6, deserve further study for 
therapeutic potential against neurodegenerative diseases. 
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